Achilles Tendinopathy Injections vs Sham: BMJ RCT & USMLE

A randomized clinical trial published in the BMJ reports that commonly used injections for Achilles tendinopathy gave no meaningful clinical benefit over a sham (simulated) procedure. The finding was covered by Medical Xpress and serves as a reminder that familiar practices need to be tested against placebo in randomized controlled trials. For USMLE candidates, it is also a good prompt to review how Achilles tendon problems are diagnosed and why some drugs can harm the tendon.

What happened

According to the news summary, investigators compared injections that are widely used for Achilles tendinopathy with a sham procedure. The injected group did not do meaningfully better clinically than the sham group.

The source material available to us is only a short summary. It does not state which injections were tested, how many patients were enrolled, how long they were followed, or which outcome scales were used. We therefore don't report any numbers or name specific agents. If you want those details, read the original BMJ paper. For exam purposes, the study design is the key point: a sham-controlled randomized trial, the strongest design for testing a procedure whose effect is judged mainly by pain.

Why it matters

Tendon pain is subjective and tends to fluctuate. Several effects can make a treatment look better than it is:

• Placebo effect. Procedures, especially injections, can produce large perceived pain relief.
• Regression to the mean. Patients usually seek care when symptoms are at their worst, so they tend to improve afterward regardless of treatment.
• Natural history. Many tendon complaints settle over time.

Without a sham arm, all of these can be mistaken for a drug effect. A sham-controlled design separates the pharmacologic or biologic effect of an injection from the ritual of receiving one. That is why a negative result like this one is informative: a treatment that is widely used and feels intuitive may still not outperform a simulated procedure.

This also fits what we know about the biology. Chronic midportion Achilles pain is usually tendinopathy (tendinosis), a degenerative process, not a primarily inflammatory one. Histology shows disorganized collagen, increased ground substance, tenocyte changes, and neovascularization, with few inflammatory cells. That is why the older term "tendinitis" is often considered a misnomer, and why anti-inflammatory approaches have limited rationale in chronic disease. The new trial does not prove this mechanism, but the two ideas are consistent.

What to know for the USMLE — high-yield points

• Tendinopathy vs tendinitis: chronic tendon pain is mostly degenerative tendinosis (collagen disorganization, little inflammation). Acute overload may have an inflammatory component.
• Location: midportion tendinopathy occurs 2–6 cm above the calcaneal insertion. Insertional tendinopathy occurs at the calcaneus and is often linked with a Haglund deformity and retrocalcaneal bursitis.
• Risk factors: overuse (running, sudden increase in training), age, obesity, poor footwear, and systemic factors such as diabetes. Drugs matter too: fluoroquinolones and corticosteroids.
• Fluoroquinolone toxicity: these drugs (ciprofloxacin, levofloxacin) inhibit bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. Their adverse effects include tendinopathy and Achilles tendon rupture. Risk is higher in patients over 60, those on systemic corticosteroids, and transplant recipients. Other classic adverse effects are QT prolongation, cartilage damage in children, and myasthenia gravis exacerbation. Tendon damage may involve tenocyte injury and increased matrix metalloproteinase activity.
• Rupture: patients often report a "pop" or a feeling of being kicked in the back of the leg. Exam shows a palpable gap and weak plantar flexion. A positive Thompson (Simmonds) test (no plantar flexion when the calf is squeezed) indicates complete rupture.
• Exam clues for tendinopathy: localized tendon thickening and tenderness, plus a painful arc sign (the tender swelling moves with ankle motion in midportion disease).
• Standard conservative management: relative rest, activity modification, and eccentric loading exercises (the Alfredson protocol) are the textbook first line. Injections are not.
• Heel pain differential:
• Plantar fasciitis: plantar heel pain worst with the first steps in the morning, tenderness at the medial calcaneal tubercle.
• Calcaneal stress fracture: pain with weight bearing, often in runners or military recruits, tender with a calcaneal squeeze.
• Sever disease (calcaneal apophysitis): active children and adolescents.
• Tarsal tunnel syndrome: tibial nerve entrapment with burning pain and paresthesias in the sole.
• Enthesitis in seronegative spondyloarthropathy: ankylosing spondylitis, reactive arthritis, psoriatic arthritis (HLA-B27 association).
• Gout and S1 radiculopathy can also present with heel or posterior ankle pain.
• Xanthomas: thickened, nodular Achilles tendons in a young adult suggest tendon xanthomas from familial hypercholesterolemia (LDL receptor defect), not tendinopathy.
• Corticosteroid injections near load-bearing tendons are classically associated with a risk of weakening and rupture. Keep this in mind for exam questions on injection complications.
• Study design: to test whether a procedure works beyond expectation, the best design is a randomized, sham-controlled, ideally blinded trial. Know placebo effect, regression to the mean, and blinding as sources of bias that such trials address.

Limitations

• Limited source detail. We only had a brief news summary. Specific injections, sample size, follow-up, outcome measures, and subgroup results are unknown to us, so we cannot say which products were tested or whether any subgroup might respond differently.
• "No meaningful benefit" is not "proven harmful." The result means no clinically important advantage over sham in this trial. It does not by itself address every injectable agent, dose, or patient population.
• One trial. A single randomized study, however well designed, is one piece of evidence. Guidelines usually change after replication and systematic review.
• Not individual advice. This article is educational and does not guide treatment decisions for any patient.

FAQ

Are injections effective for Achilles tendinopathy?

In the BMJ trial described in the news summary, commonly used injections did not give a meaningful clinical benefit over a sham procedure. The summary does not say which injections were studied, so check the original paper for specifics.

Is Achilles tendinopathy the same as tendinitis?

Not usually. Chronic Achilles pain is typically tendinosis, a degenerative change with collagen disorganization and few inflammatory cells. "Tendinitis" implies primary inflammation, which is less common in chronic cases.

Which drugs are linked to Achilles tendon rupture on the USMLE?

Fluoroquinolones are the classic answer, with higher risk in older patients, in those taking corticosteroids, and in transplant recipients. Corticosteroids themselves are also associated with tendon weakening.

Key takeaways

• A BMJ randomized trial reported that commonly used Achilles tendinopathy injections were no better than a sham procedure. Detailed numbers and agents were not available in our source.
• Chronic Achilles pain is mainly degenerative tendinosis, and textbook first-line care is eccentric loading exercise and load management.
• For the USMLE, link Achilles problems with fluoroquinolone and corticosteroid tendon toxicity, the Thompson test, the heel pain differential, and the value of sham-controlled RCTs.